The Beacon Award for Women Leaders in Oncology

The AIM-HI Beacon Award for Women Leaders in Oncology recognizes outstanding women leaders in all sectors of the health and life sciences industry who have made a significant impact on advancing cancer treatment, detection, and diagnosis for patients worldwide through the development and commercialization of novel technologies and/or implementation of public policy.

The 2022 Beacon Award prize recipient will be honored and awarded an authentic gold medal at a Luncheon Award Ceremony at the National Press Club in Washington DC on October 22, 2022. In addition, AIM-HI will provide $20,000 for an Emerging Women Leaders Fellowship — named after the yearly Beacon Award recipient — to honor and support promising young women scholars from specific universities and institutions across the areas of cancer research, biotechnology, healthcare public policy, and  entrepreneurship in healthcare & life sciences.

All nomination information will be kept confidential, and be reviewed and evaluated by the distinguished Beacon Award Selection Committee, comprising of physician-scientists, successful entrepreneurs, and prominent business leaders in the health & life sciences industry. Nominations will be assessed according to the following criteria:

  • Sustained commitment and leadership for cancer research, development and commercialization of innovative products
  • Advocacy for and implementation of public policy to benefit cancer patients
  • Encouragment, advocacy and inspiration of other women
  • Impact on cancer patients, their families and community
AIM-HI Beacon Award Selection Committee Members
  • Sujuan Ba, Ph.D., Co-Chair, CEO & Co-Founder, AIM-HI Accelerator Fund; President & CEO, National Foundation for Cancer Research
  • Webster Cavenee, Ph.D., Co-Chair, Distinguished Professor Emeritus, University of California San Diego
  • Deborah Dunsire, M.D., President & CEO, Lundbeck
  • Karen Knudsen, MBA, Ph.D., CEO, American Cancer Society
  • Andrew Plump, M.D., Ph.D., President, Research & Development, Takeda Pharmaceutical
  • Daniel Von Hoff, M.D., F.A.C.P., Distinguished Professor, Translational Genomics Research Institute (TGen)
Support Our Mission

Together, we can make the next generation of cancer treatments a reality.

Back To Top